Large Cap Biopharmaceutical Growth Stocks With the MoMo days over the next earnings cycle (Q1,Q2 2014) should give us better clarity on winners for 2014.On the last day of March all of these large caps rallied after a severe one week correction from 3/21-28. Watch the technicals this week for bargain hunting, for example, Amgen, […]
12:15p EDT 3/26 With NASDAQ down 0.64% and the IBB down 0.6% here are some green stocks: Rayno Life Science Portfolio: AMGN up 0.53%, CPHD up 1.43%, GILD up 0.57%, and REGN up 0.84%. Other Notables on our watch list: CLVS up 4%, CONX up 11%, FMI up 2.7%, KERX up 17%, NSPH up 1.9%, […]
(See Full Article in Seeking Alpha 3/26) Biopharmaceutical Downdraft 15% From February Highs (IBB$239) Large Cap Biopharmaceutical Stocks Are Core Holdings: ABBV, AMGN, GILD The biotech frenzy of MoMo investing is over so it is time to invest longer term with quality companies. If the sector can hold at February lows, even treading water could […]
Biotech Stocks Will Need To Rebuild Confidence With Momentum Gone Damage on Friday 3/21 was considerable but most indices/ETFs are above 2014 Feb 6 low: FBIOX ($206.4) Up 13.6% YTD, FEB 5 low $196.24 IBB ($246) Up 8.35% YTD, FEB 6 low $237. PBE ($43.33) Up 16.94% YTD, FEB 5 low $40.32 XBI ($153) Up 17.6% […]
Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer and 42% with pre-cancerous lesions. (See detailed data). 2015 revenue forecasts from […]
XBI Outperforms FBIOX YTD Many biotech stocks sold off today despite a strong market on weak volume as industrials and tech were up about 1.4%. Watch the ETFs compared to Fidelity FBIOX because the sector is more volatile this month. Here is a chart comparing three ETFs: XBI took off in January racing ahead of […]
It has been a warm and dry snow season in the Sierras but the Mammoth season was saved by two decent storms in February with 68.5 inches bringing the season total to 158 in of snow.Last year another dry season dropped 308 in with a big December.The next mark is 2011-12 with only 263 in and […]
March 17 Update –GREEN DAY with Geopolitical risk on back burner As of 11.38a EDT Industrials lead up 1%, healthcare up 0.8%, IBB up 1.33% Biopharmaceuticals stocks were strong with Rayno large cap picks: Alexion (ALXN $117) up 1.45%, Amgen (AMGN $125) up 1.9%, Biogen Idec (BIIB $345) up 3.8%, Gilead (GILD $76); Rayno Life Science […]
Mini-Rally in Life Science Stocks— Update 10p PDT Biotech stocks recovered off their am lows today with major ETFs (FBT,IBB,XBI ($161.45) up about 0.3% and within 5% of highs. Over the past week or so biopharma stocks have been weak with a “topping” process evident in late February. Volatility has increased with daily swings and some mid-cap […]
Big Large Cap Winners Down-Volatilty Increasing ETFS: IBB $257 down 1.57%, PBE $45.25 down 1.2% , XBI $159.7 down 1.17% The profit taking which actually began last Friday and, after a brief recovery, resumed yesterday accelerating today. Large caps are leading the way down. Notable losers within the Rayno Portfolio are: Biogen Idec (BIIB $326.27) […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.